Company profile
The company is committed to drug research and development, production, marketing and technical services. The company has GSP, GMP certification qualification, the current products are mainly concentrated in the field of neuroprotective agents and geriatric disease treatment, mainly engaged in: monosialic acid tetrahexose ganglioside sodium injection, brain protein hydrolysate for injection, clindamycin phosphate for injection, pantoprazole sodium for injection and milinone injection and so on. After years of efforts, the company has established its own characteristics and advantages in biochemical and plant drug extraction, nervous system drugs, antibiotic drugs and chiral drug research and development, and obtained a number of approval documents for biochemical drugs, nervous system drugs and antibiotic drugs. and declared a number of chiral drug projects such as L-pantoprazole sodium, esomeprazole sodium, dexoprazole and so on, enriching the company's variety reserve.
The highlight of the company
(1) the company's R & D department has established four R & D technology platforms, namely, biological extraction, chiral drugs, proton pump inhibitor freeze-dried powder injection and long-acting injection, and has developed and mastered various core technologies based on the above platform. including biological extraction and purification technology, chiral drug synthesis technology, lipid microsphere preparation technology, preparation freeze-drying technology, impurity separation and identification technology and modern analysis and detection technology. It strongly supports the rapid development of the company's business, and lays a technical foundation for the application of production approval documents for a variety of APIs and preparations in the future.
(2) the company widely attracts talents, establishes high-quality R & D team, takes the medical R & D center as the platform, and strengthens the cooperation with colleges and universities and scientific research institutes. In terms of scientific research investment, the company does not set an upper limit on capital investment, only on the advantages and disadvantages of the project. In terms of hardware construction, it has equipped with perfect experimental, inspection, pilot-scale and office facilities, introduced advanced design concepts, and created a first-class and modern experimental office environment. The pharmaceutical R & D center currently has a perfect synthesis laboratory, high-end synthesis equipment and preparation research sites and equipment with complete dosage forms, and the center has dozens of HPLC, GC, and a number of high-end analytical precision instruments, such as HPLC-MS, GC-MS, which are the most advanced in performance.
(3) the company adopts the distribution model, which greatly reduces the operating risk and management cost compared with the independent business model, and helps to reduce the financial pressure of the company. The company's main products include brain protein hydrolysate for injection, GM1 injection and so on, all of which are commonly used in cardio-cerebrovascular drugs. The company pays attention to the comprehensive strength of dealers in terms of resources, capital, expertise and willingness to cooperate, which can help the company distribute and accompany the growth of the enterprise. After years of accumulation, the company's dealer team is loyal and relatively fixed, which is conducive to the sustainable development of the company's products.